<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991909</url>
  </required_header>
  <id_info>
    <org_study_id>HRS4800-103</org_study_id>
    <nct_id>NCT04991909</nct_id>
  </id_info>
  <brief_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of HRS4800 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of HRS4800 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the safety and tolerability of HRS4800 after multiple&#xD;
      oral administration with different dose regimens in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HRS4800 Tablet compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of the Adverse Events that are related to the treatment from baseline to Day36</measure>
    <time_frame>from baseline to Day36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The severity of the Adverse Events that are related to the treatment from baseline to Day36</measure>
    <time_frame>from baseline to Day36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Peak Concentration;</measure>
    <time_frame>Day1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tau, Area under the curve during a dose interval;</measure>
    <time_frame>Day1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax; The time to reach peak concentration;</measure>
    <time_frame>Day1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,max, Peak Concentration at steady state;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss, 0-tau, Area under the curve during a dose interval at steady state;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf, Area under the curve from 0 to infinite;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, the time to reach peak concentration;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough trough concentration at steady state;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac, , accumulation factor;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2, terminal half life;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F, apparent clearance at steady state ;</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss/F; apparent volume of distribution at steady state</measure>
    <time_frame>Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHR175593 concentration on Day1 and day 14</measure>
    <time_frame>Day1 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc on Day1 and Day 14</measure>
    <time_frame>Day1 and day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS4800</intervention_name>
    <description>HRS4800</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Males and females aged between 18 years and 55 years at screening, inclusive.&#xD;
&#xD;
          3. Meet the weight standard&#xD;
&#xD;
          4. Agree to take effective contraceptive methods&#xD;
&#xD;
          5. No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, laboratory tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe infections, injuries or surgeries or plan to undergo any surgeries.&#xD;
&#xD;
          2. ALT, AST, ALP or total bilirubin level abnormal&#xD;
&#xD;
          3. Estimated Glomerular Filtration Rate (eGFR, using CKD-EPI Creatinine Equation) is&#xD;
             abnormal&#xD;
&#xD;
          4. Subject's supine systolic BP is &gt;140 mmHg or &lt;90 mmHg; diastolic BP &gt;90 mmHg or &lt;40&#xD;
             mmHg at screening/baseline visits or before dosing.&#xD;
&#xD;
          5. Subjects with cardiac and Cerebrovascular Disease&#xD;
&#xD;
          6. Positive nicotine test&#xD;
&#xD;
          7. History of regular alcohol consumption in the past 1 month exceeding an average weekly&#xD;
             intake of 21 standard drinks&#xD;
&#xD;
          8. Positive drug screening tests&#xD;
&#xD;
          9. Positive infectious diseases screening tests&#xD;
&#xD;
         10. plan to use of any other medicine during the trial&#xD;
&#xD;
         11. Whole blood donation or loss of more than 200 mL of blood within 1 month&#xD;
&#xD;
         12. blood transfusion in the past 2 months&#xD;
&#xD;
         13. History of allergy to the study drug or any component of it.&#xD;
&#xD;
         14. Can't accept assigned meals during the trial&#xD;
&#xD;
         15. Treatment with an investigational drug within 30 days (or 5 half-lives, whichever is&#xD;
             longer) of dosing.&#xD;
&#xD;
         16. poor tolerance or difficult for vein blood collection&#xD;
&#xD;
         17. Other conditions or laboratory abnormality that may increase the risk associated with&#xD;
             study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

